Skip to main content
. Author manuscript; available in PMC: 2006 Jan 25.
Published in final edited form as: Pharm Res. 2005 Nov 3;22(12):2107–2114. doi: 10.1007/s11095-005-8343-0

Figure 1.

Figure 1

Plasma concentrations versus time profiles of 111indium oxine-labeled poly(ethylene oxide)-modified poly(ɛ-caprolactone) (PCL) nanoparticles (▪) and poly(ethylene oxide)-modified poly(β-amino ester) (PbAE) (♦) nanoparticles in mice.